Published in Hepatitis Weekly, December 3rd, 2007
"Graft survival and histological endpoints (severe activity and fibrosis) of HCV infection in the allografts...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-12-03)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.